Recent Updates
Recently added Catalysts
ILMN Positive Sentiment Score: 70/100

Illumina Announces Preliminary Results of Annual Meeting Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25 , 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing

Key Takeaway: Illumina has announced preliminary results from its 2023 Annual Meeting, where shareholders re-elected eight of nine directors, including new board member Andrew Teno. The company received positive votes for various proposals, but notably, the say-on-pay proposal was not approved. These results are preliminary and await final certification by an independent Inspector of Elections. Illumina expressed gratitude to shareholders for their support and emphasized transparency and communication moving forward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Shareholders re-elected eight out of nine director nominees, showing strong support for the current leadership.
  • The appointment of Andrew Teno from Icahn Capital LP is seen as a positive addition to the board.
  • Illumina's commitment to improving human health by unlocking the power of the genome reinforces its mission and public image.

Full Press Release Details

Illumina Announces Preliminary Results of Annual Meeting
Illumina shareholders re-elect eight of nine Illumina directors
SAN DIEGO, May 25, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today
announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina director nominees - Francis deSouza, Robert Epstein, MD, Frances
Arnold, PhD, Caroline Dorsa, Scott Gottlieb, MD, Gary Guthart, PhD, Philip Schiller, and Sue Siegel - as well as Andrew Teno, to the Board of Directors. The Board thanks John Thompson for his board tenure and extraordinary leadership.
Illumina issued the following statement:
"Illumina thanks shareholders for their continued support of the company, which remains committed to its mission of improving human health by unlocking the power
of the genome. We appreciate the constructive shareholder feedback throughout this process and are committed to delivering on our plan to accelerate shareholder value creation. We will continue to provide transparent and e ective communication as
we move forward together.
We would like to welcome Andrew Teno, a portfolio manager at Icahn Capital LP, to the Board and look forward to productive and collaborative engagement.
We also thank John Thompson for his years of service and contributions to Illumina as Chair of the Board. His deep executive experience and business knowledge
were greatly valued during his tenure. John brought extensive technology leadership, including as a CEO at Symantec and Virtual Instruments, and Chairman of the Board at Microsoft, to Illumina. His depth and breadth of knowledge in technology and
across a number of private and public sectors, as well as his nancial expertise, greatly contributed to the Board's strategic leadership of the company."
The company also noted that shareholders approved the proposal to ratify auditors, one-year frequency on say-on-pay, and the stock incentive plan proposal; and shareholders did not
approve the company's say-on-pay proposal.
The results announced today are considered preliminary and are subject to certi cation by the independent Inspector of Elections. The nal certi ed results are expected to be
provided in a Current Report led on Form 8-K with the U.S. Securities and Exchange Commission within the next four business days.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the
future, business plans and other statements that are not historical in nature. These statements are made on the basis of Illumina's views and assumptions regarding future events and business performance and plans as of the time the statements are
made. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential,"
"project," "target," "will" and other words and terms of similar meaning. Illumina does not undertake any obligation to update these statements unless required by applicable laws or
regulations, and you should not place undue reliance on forward-looking statements. Speci c factors are set forth in Illumina's Annual Report on Form 10-K for the year ended January 1, 2023 under the caption "Risk Factors", in information disclosed
in public conference calls, the date and time of which are released beforehand, and in lings with the Securities and Exchange Commission including, among others, quarterly reports on Form 10-Q.
Gladstone Place Partners

Frequently Asked Questions

Who were re-elected as Illumina directors?

Eight of nine nominees were re-elected, including Francis deSouza and Robert Epstein.

What was the outcome of the say-on-pay proposal?

The shareholders did not approve the company's say-on-pay proposal.

Who is Andrew Teno?

Andrew Teno is a new board member and a portfolio manager at Icahn Capital LP.

What is Illumina's mission?

Illumina aims to improve human health by unlocking the power of the genome.

When will final election results be available?

Final certified results are expected within four business days after the meeting.

Last updated: May 25, 2023